# UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

> **NCT04714060** · PHASE2 · UNKNOWN · sponsor: **UBP Greater China (Shanghai) Co., Ltd** · enrollment: 44 (estimated)

## Conditions studied

- Recurrent Genital Herpes

## Interventions

- **BIOLOGICAL:** UB-621

## Key facts

- **NCT ID:** NCT04714060
- **Lead sponsor:** UBP Greater China (Shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-01-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04714060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04714060, "UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04714060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*